The IQVIA Podcast

In this episode of the IQVIA podcast, Daniel Mora-Brito, Engagement Manager, Global Health, Thought Leadership, examines the growing urgency of addressing obesity as a central driver of noncommunicable diseases (NCDs), particularly in low- and middle-income countries (LMICs) and what is at stake if action is delayed. Joined by Johanna Ralston, CEO, World Obesity Federation; Claudia Martínez, Director of Research, Access to Medicine Foundation; and Helen McGuire, Global Lead, NCDs, PATH, the discussion explores how governments and global institutions can elevate obesity within national and global NCD agendas through stronger advocacy, policy prioritization, prevention, and system level responses. The conversation also unpacks the evolving role of treatment and innovation and outlines the concrete steps needed to ensure access is equitable, sustainable, and aligned with long term public health goals.Enjoyed this content? Check out out white paper "Expanding the toolbox for obesity prevention and treatment in low- and middle-income countries: What does it take to make it happen?" for further insights.

Marie Flanagan, Regulatory and AI governance lead at IQVIA Safety Technologies with ~20 years in pharmacovigilance, talks about aligning AI with regulatory frameworks. She covers shared responsibility across teams. She explains platform-level governance and seven guiding principles. She highlights continuous monitoring, human-in-loop design, bias detection, and baking guardrails into system design.

Join IQVIA Thought Leaders, Sarah Rickwood and Kirstie Scott as they discuss key changes in the launch environment. Hear about the rising importance of the private market (led by, but not limited to obesity medications) and how pharma must quickly adapt to AI-enabled HCP self-empowerment.

In this episode, Dr. Paul Beresford, Senior Vice President of Biopharma Partnerships at PathAI, shares perspectives on how artificial intelligence is transforming pathology workflows, enhancing diagnostic accuracy, and supporting precision medicine. Discover practical insights on AI integration, regulatory alignment, and the evolving partnership between technology and clinical expertise in diagnostics.Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Paul Beresford, Ph.D., Senior Vice President of Biopharma Partnerships, PathAI

In this episode, Stefan Lutzmayer, from IQVIA’s EMEA Thought Leadership team, speaks with Özgür Tuncer, CEO & Executive Director of Stablepharma, about the growing complexity of the pharmaceutical cold chain and how innovation could make it more resilient, sustainable, and accessible.IQVIA’s EMEA Thought Leadership team analyses major trends shaping the pharmaceutical market and their implications for healthcare systems and companies across the region.You’ll hear about:Why “keeping it cold” is more than logistics—it’s about safety, equity and sustainability.Where breakdowns happen in practice, from transport to site of administration.Why the cold chain is not just an issue of low- and middle-income countries.How hidden costs and emissions make the cold chain a big topic for healthcare systems around the world.The promise of thermostable technology to reduce waste, cut costs and expand access globally.Listen in for practical insights on how the next decade of cold-chain innovation could reshape the future of biologics and global health.For more insights, read IQVIA’s white paper “Tip of the Iceberg: Economic and Environmental Impact of the Vaccine Cold Chain.”

Welcome to “Debunking Value, Access & Pricing Myths”—a podcast series from IQVIA’s Value and Payer Evidence team where we explore the transformations underway in healthcare pricing and market access - challenging outdated norms and shedding light on the new realities shaping our work.In the second episode, your host Rebecca Coady, Principal at IQVIA, is joined by her colleague Katrin Lamp. Together, they take on a myth “Pricing in Germany is always transparent.”Katrin, who is a principal at IQVIA and an expert in the German market, shares her perspectives on the major changes to drug pricing in the largest EU pharmaceutical market, Germany, and what this means for pricing strategy development and price management – they cover what you need to know about the changing pricing rules, including the opportunity for confidential pricing.

In this episode presented by IQVIA, BioSpace’s head of insights Lori Ellis discusses the importance of target product profiles, particularly when navigating funding challenges, with Ian Fisher, head of development analytics.

In this episode, BioSpace’s head of insights Lori Ellis discusses how AI transformation can help organizations navigate a rapidly evolving regulatory environment with senior director of regulatory innovation and technology, Michelle Gyzen.

In this episode, BioSpace’s head of insights Lori Ellis discusses the FDA’s first draft guidance for AI in drug development, published in January 2025, with Archana Hegde, Senior Director, PV systems and innovations at IQVIA.

In this episode, BioSpace’s head of insights Lori Ellis discusses the evolving role of local qualified persons for pharmacovigilance with ⁠Ana Pedro Jesuíno⁠, global head local QPPV network at IQVIA.